3/13/2024 | EM | S&P raises Glenmark Pharmaceuticals
|
11/18/2021 | CVEM | S&P ups Glenmark Pharmaceuticals
|
4/12/2021 | CVLM | Glenmark Pharmaceuticals obtains consents for tender for 2% convertibles due 2022
|
3/19/2021 | CVLM | India’s Glenmark starts tender offer for 2% equity-linked securities
|
1/4/2021 | EMLM | India’s Glenmark to redeem $10 million of 4½% notes due 2021
|
12/1/2020 | EMLM | India’s Glenmark to redeem $7.5 million of 4½% notes due 2021
|
11/24/2020 | CVEM | S&P takes Glenmark Pharmaceuticals off watch
|
11/20/2020 | EMLM | Glenmark to redeem $182.5 million of outstanding 4½% notes due 2021
|
7/29/2020 | CVEM | S&P puts Glenmark Pharmaceuticals on watch
|
7/9/2020 | CVEM | Fitch pulls Glenmark bond rating
|
2/11/2020 | EM | India’s Glenmark Pharmaceuticals board to consider raising funds
|
1/14/2020 | CVEM | Fitch rates Glenmark notes BB
|
1/14/2020 | CVEM | S&P assigns Glenmark notes BB-
|
9/17/2019 | CVEM | S&P revises Glenmark view to negative
|
10/1/2018 | CVLM | Glenmark buys back $86.5 million 2% convertibles in one-day tender
|
9/28/2018 | CVLM | Glenmark holds one-day tender offer for $100 million 2% convertibles
|
7/12/2018 | CVEM | Fitch affirms Glenmark, notes
|
3/1/2018 | CVEM | S&P downgrades Glenmark
|
12/11/2017 | CV | Glenmark sets exchange rate for $200 million 2% convertibles due 2022
|
12/5/2017 | CV | Glenmark sets conversion price for $200 million of 2% six-year notes
|
7/14/2017 | CVEM | Fitch revises Glenmark to stable
|
5/25/2017 | CVEM | S&P: Glenmark view to negative
|
7/27/2016 | CV | Glenmark greenshoe ups 2% six-year convertibles deal to $200 million
|
7/18/2016 | CVEM | S&P rates Glenmark notes BB
|
7/18/2016 | EM | Glenmark Pharmaceuticals plans to issue $200 million unsecured bonds
|
7/18/2016 | CVEM | Fitch rates Glenmark notes BB
|
6/1/2016 | CV | New Issue: India’s Glenmark prices $170 million six-year convertibles with 2% coupon, up 20%
|
10/29/2015 | CV | India’s Glenmark Pharmaceuticals OKs up to $500 million convertibles
|
9/2/2009 | CV | Glenmark Pharmaceuticals obtains approval for convertible instruments
|
7/27/2009 | CV | Glenmark Pharmaceuticals OKs up to $250 million convertible bonds
|
10/10/2007 | CV | Glenmark Pharmaceuticals approves plan to issue convertibles
|
8/24/2006 | BT | Glenmark gets FDA approval to market generic anti-convulsant Gabapentin
|
8/3/2006 | BT | Napo, Glenmark to start phase 2 acute infectious diarrhea trial in India
|
7/20/2006 | BT | Mylan, Glenmark, Cadila, Teva to sell generic Mobic for osteoarthritis
|
7/17/2006 | BT | Glenmark, Merck to co-develop, market dermatological products for European market
|
6/5/2006 | BT | Glenmark, Paul Capital Partners sign royalty deal for $27 million to build generic dermatology portfolio
|
5/8/2006 | BT | Glenmark acquires marketing rights to three generic products for pain from Aspen
|
5/2/2006 | BT | Glenmark acquires marketing rights to two generic products for pain from Lehigh Valley
|
4/27/2006 | BT | Glenmark enters phase 2 studies for asthma treatment Oglemilast
|
2/24/2006 | BT | Glenmark reports positive phase 1 results for anti-diabetic inhibitor GRC 8200
|
2/13/2006 | BT | Glenmark to file patent for obesity drug candidate
|
12/20/2005 | BTCVEM | New Issue: India's Glenmark Pharma sells $30 million five-year convertibles to yield 0%, up 35%
|
12/15/2005 | BT | Glenmark signs deal with InvaGen to develop, market seven generics for U.S. market
|
10/26/2005 | BT | Glenmark Pharmaceuticals acquires Argentinean company Servycal
|
2/1/2005 | CVEM | New Issue: India's Glenmark prices $70 million convertibles
|
12/13/2004 | CVEM | India's Glenmark to issue up to $100 million convertibles
|
12/7/2004 | CVEM | India's Glenmark Pharmaceuticals considering convertible offering
|